This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Diagnostic criteria for polycythaemia vera

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Polycythaemia vera is a myeloproliferative neoplasm known to be associated with dysregulated signalling of the Janus associated kinases JAK1 and JAK2.

Recommended diagnostic criteria for PV

JAK2-positive polycythaemia vera (requires both criteria)

  • A1 High haematocrit (> 0.52 in men, > 0.48 in women) OR raised red cell mass (>25% above predicted)
  • A2 Mutation in JAK2

JAK2-negative polycythaemia vera (requires A1- A4 plus another A or two B criteria) *

  • A1 Raised red cell mass (>25% above predicted) OR haematocrit >=0.60 in men, >=0.56 in women
  • A2 Absence of mutation in JAK2
  • A3 No cause of secondary erythrocytosis
  • A4 Bone marrow histology consistent with polycythaemia vera
  • A5 Palpable splenomegaly
  • A6 Presence of an acquired genetic abnormality (excluding BCR-ABL1) in the haematopoietic cells
  • B1 Thrombocytosis (platelet count >450 x 10^9/l)
  • B2 Neutrophil leucocytosis (neutrophil count >10 x 10^9/l in non-smokers, >=12.5 x 10^9/l in smokers)
  • B3 Radiological evidence of splenomegaly
  • B4 Low serum erythropoietin

*This is a very rare clinical entity


McMullin MF et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.British Journal of Haematology, 2019, 184, 176-191

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.